UK markets closed

Ipsen S.A. (0MH6.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
92.89-0.06 (-0.06%)
At close: 06:19PM BST
Full screen
Previous close92.95
Open92.55
BidN/A x N/A
AskN/A x N/A
Day's range92.55 - 92.55
52-week range92.55 - 92.55
Volume1,678
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

    Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP PDUFA date has been set for 16 August 2023 following the New Drug Application resubmission containing additional information on palovarotene clinical trial data, requested in a complete response letter to Ipsen in December 2022 PARIS, FRANCE, 16 March 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA)

  • Globe Newswire

    Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital

    Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 28 February 2023 83,814,526 Gross total* of voting rights: 132,091,376 Net tot

  • Globe Newswire

    Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

    Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Bringing medicines to patients with rare liver disease, a growth opportunity for IpsenLead asset Bylvay® (odevixibat) is the first approved treatment in progressive familial intrahepatic cholestasis, with two additional investigational indications in rare, pediatric liver diseases Acquisition adds novel bile-acid modulators and an innovative pipeline to the existing rare liver portfolio PARIS, FRANCE, 3 Mar